{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086086","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.262312+00:00","generated_at":"2026-05-31T12:21:05.370554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioXcel Q2 2024 IGALMI net revenue up 141% YoY to $1.1M; net loss narrows to $8.3M","bullets":["IGALMI net revenue $1.1M (+141% YoY, +90% sequentially) on increased psychiatric clinic contracting.","Net loss $8.3M vs $53.5M in Q2 2023; operating cash used $23.2M; cash $56.3M at June 30.","Planning SERENITY At-Home Phase 3 for BXCL501 in agitation with bipolar/schizophrenia; TRANQUILITY In-Care Phase 3 for Alzheimer's agitation.","IGALMI PMR study showed no tachyphylaxis/tolerance/withdrawal; no serious adverse events reported.","Received USPTO Notice of Allowance for new patent expiring 2043, expected as 11th Orange Book listing for IGALMI."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086086","json":"https://secwatch.observer/filing/0001104659-24-086086.json","markdown":"https://secwatch.observer/filing/0001104659-24-086086.md","text":"https://secwatch.observer/filing/0001104659-24-086086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/0001104659-24-086086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/tm2420782d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:21:05.370554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}